However, the clinical efficacy of mitogen-activated protein kinase (MAPK) pathway inhibitors (MAPKi) for MAP2K1-mutant tumors is not well defined. We sought to characterize the genomic and clinical ...

The degree of complexity and crossover within MAPK signaling, and also shifts in pathways such as nuclear factor κB signaling, could also explain the modest effect of p38 inhibitors. The p38α ...

inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK pathway, according to a study published in JACC ...

Gomekli is an oral small molecule designed to block MEK1 and MEK2, two proteins that play key roles in the MAPK pathway. MEK inhibitors have already been approved for treating certain cancers.

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

“With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further establish our leadership in targeting RAS/MAPK pathway-driven ...

The company is focused on developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers ... This BRAF/CRAF inhibitor is being evaluated in a Phase 3 study called ...

(C) PFS and (D) OS in class 2 versus other MAP2K1 mutant tumors in patients treated with MEK inhibitor–containing ... mutations may be sensitive to MAPK TT, however, only when the universally ...